Preoperative lanreotide treatment improves outcome in patients with acromegaly resulting from invasive pituitary macroadenoma

Journal of International Medical Research

Volumn 40, Issue 2, 2012, Pages 517-524

  Li, Z Q ^a,b   Quan, Z ^a,b   Tian, H L ^a   Cheng, M ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b ANHUI UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Acromegaly; Lanreotide; Pituitary Macroadenoma; Preoperative Treatment

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; SOMATOMEDIN C;

ACROMEGALY; ADULT; AGED; ARTICLE; CANCER INVASION; CANCER REGRESSION; CEREBROSPINAL FLUID RHINORRHEA; CONTROLLED STUDY; DIABETES INSIPIDUS; DRUG DOSE INCREASE; ENDOCRINE FUNCTION; FEMALE; HUMAN; HYPOPHYSIS ADENOMA; INVASIVE PITUITARY MACROADENOMA; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; RANDOMIZED CONTROLLED TRIAL; TRANSSPHENOIDAL SURGERY; TUMOR VOLUME;

EID: 84860431672     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001204000213     Document Type: Article

References (34)

1. Meij BP, Lopes MS, Ellegala DB, et al: The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. J Neurosurg 2002; 96: 195-208.
2. Gong J, Zhao Y, Abdel-Fattah R, et al: Matrix metalloproteinase-9, a potential biological marker in invasive pituitary adenomas. Pituitary 2008; 11: 37-48.
3. Lundin P, Pedersen F: Volume of pituitary macroadenomas: assessment by MRI. J Comput Assist Tomogr 1992; 16: 519-528.
4. Kaltsas GA, Grossman AB: Malignant pituitary tumours. Pituitary 1998; 1: 69-81.
5. Daly AF, Rixhon M, Adam C, et al: High prevalence of pituitary adenomas: a cross-sectional study in the province of Liège, Belgium. J Clin Endocrinol Metab 2006; 91: 4769-4775.
6. Buchfelder M: Management of aggressive pituitary adenomas: current treatment strategies. Pituitary 2009; 12: 256-260.
7. Melmed S: Medical progress: acromegaly. N Engl J Med 2006; 355: 2558-2573.
8. Nomikos P, Buchfelder M, Fahlbusch R: The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol 2005; 152: 379-387.
9. Shou XF, Li SQ, Wang YF, et al: Treatment of pituitary adenomas with a transsphenoidal approach. Neurosurgery 2005; 56: 249-256.
10. Lamberts SW, Hofland LJ: Future treatment strategies of aggressive pituitary tumors. Pituitary 2009; 12: 261-264.
11. Melmed S, Sternberg R, Cook D, et al: A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 2005; 90: 4405-4410.
12. Maiza JC, Vezzosi D, Matta M, et al: Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol (Oxf) 2007; 67: 282-289.
13. Vance ML, Laws ER Jr: Role of medical therapy in the management of acromegaly. Neurosurgery 2005; 56: 877-885.
14. Turner HE, Thornton-Jones VA, Wass JA: Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly. Clin Endocrinol (Oxf) 2004; 61: 224-231.
15. Shen M, Shou X, Wang Y, et al: Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study. Endocr J 2010; 57: 1035-1044.
16. Colao A, Pivonello R, Marzullo P, et al: Severe systemic complications of acromegaly. J Endocrinol Invest 2005; 28: 65-77.
17. Vieira JO Jr, Cukiert A, Liberman B: Evaluation of magnetic resonance imaging criteria for cavernous sinus invasion in patients with pituitary adenomas: logistic regression analysis and correlation with surgical findings. Surg Neurol 2006; 65: 130-135.
18. Cook DM, Ezzat S, Katznelson L, et al: AACE Medical Guidelines for Clinical Practice for the diagnosis and treatment of acromegaly. Endocr Pract 2004; 10: 213-225.
19. Knosp E, Steiner E, Kitz K, et al: Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 1993; 33: 610-618.
20. Lissett CA, Peacey SR, Laing I, et al: The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma. Clin Endocrinol (Oxf) 1998; 49: 653-657.
21. Shimon I, Cohen ZR, Ram Z, et al: Transsphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients. Neurosurgery 2001; 48: 1239-1245.
22. Beckers A: Does preoperative somatostatin analog treatment improve surgical cure rates in acromegaly? A new look at an old question. J Clin Endocrinol Metab 2008; 93: 2975-2977.
23. Sheppard MC: Primary medical therapy for acromegaly. Clin Endocrinol (Oxf) 2003; 58: 387-399.
24. Thapar K, Kovacs K, Scheithauer BW, et al: Diagnosis and management of pituitary tumors. In: Pituitary Surgery (Thapar K, Edward R, eds). Totowa, NJ: Humana Press, 2001; pp 239.
25. Abe T, Lüdecke DK: Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur J Endocrinol 2001; 145: 137-145.
26. Bevan JS: Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 2005; 90: 1856-1863.
27. Karavitaki N, Turner HE, Adams CB, et al: Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clin Endocrinol (Oxf) 2008; 68: 970-975.
28. Mao ZG, Zhu YH, Tang HL, et al: Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial. Eur J Endocrinol 2010; 162: 661-666.
29. Comets E, Mentré F, Grass P, et al: Population pharmacodynamic analysis of octreotide in acromegalic patients. Clin Pharmacol Ther 2003; 73: 95-106.
30. Astruc B, Marbach P, Bouterfa H, et al: Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. J Clin Pharmacol 2005; 45: 836-844.
31. Lorcy Y, Dejager S, Chanson P, For French Octreotide LAR Group: Time course of GH and IGF-1 levels following withdrawal of long-acting octreotide in acromegaly. Pituitary 2000; 3: 193-197.
32. Bex M, Abs R, T'Sjoen G, et al: AcroBel - the Belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects. Eur J Endocrinol 2007; 157: 399-409.
33. Trainer PJ: Editorial: acromegaly - consensus, what consensus? J Clin Endocrinol Metab 2002; 87: 3534-3536.
34. Carlsen SM, Lund-Johansen M, Schreiner T, et al: Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab 2008; 93: 2984-2990.